[Effects of Cuban analog (SWR-104SA), a new histamine H2 receptor antagonist, on gastric acid secretion and experimental ulcer formation]. 1996

R Shinkawa, and T Kiso, and H Kataoka, and T Isoi, and T Kakita, and T Shogaki, and Y Ohtsubo
Research Department, Sawai Pharmaceutical Co. Ltd., Osaka, Japan.

The antagonism of histamine H2-receptor by SWR-104SA (1'-bromo-N-[3-[3-(1-piperidinylmethyl) phenoxy] propyl]-spiro [1,3-dioxolane-2,9'-pentacyclo-[4.3.0.0.(2,5)0.(3,8) 0.(4,7)]nonane]-4'-carboxamide monooxalate) was estimated using the isolated guinea-pig atrium and gastric acid secretion in rats. The concentration-response curves for the positive chronotropic effect of histamine on the atrium were displaced to the right in parallel without change in the maximum response by SWR-104SA and roxatidine acetate hydrochloride (roxatidine). The pA2 values of SWA-104SA and roxatidine acetate hydrochloride were 7.27 and 7.38, respectively. The slopes of the regression line of log (DR-1) against log SWR-104SA and roxatidine concentration were 1.00 and 0.92, respectively. There was no significant difference between the two compounds with respect to the histamine H2-receptor antagonism and/or binding manner in vitro. In the rat gastric fistula model stimulated by histamine, however, antisecretory potency of SWR-104SA was 3 times less than that of roxatidine. SWR-104SA given p.o. prevented the formation of gastric lesion induced by HCl-ethanol and indomethacin dose-dependently, roxatidine also prevented its formation by HCl-ethanol, but failed to prevent that by indomethacine. These antiulcer activities of SWR-104SA were shown at the lesser doses of antisecretory activity. On the other hand, roxatidine did not prevent the ulcer formation at the same dose level of antisecretory activity. These results indicate that the antiulcer effect of SWR-104SA is not caused by the antisecretory action alone. In addition, the mucosal protective activity of SWR-104SA for HCl-ethanol induced gastric lesion was independent of endogenous prostaglandins. Moreover SWR-104SA had inhibitory effects on indomethacin-induced gastric hypermotility in rats. These actions may partly explain the gastric protection of this compound and additional mechanisms such as mucosal blood flow could be involved in the antiulcer efficacy. Consequently, it appears that SWR-104SA is a new antiulcer drug that exerts a potent cytoprotective effect in addition to its gastric antisecretory activity.

UI MeSH Term Description Entries
D007213 Indomethacin A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES. Amuno,Indocid,Indocin,Indomet 140,Indometacin,Indomethacin Hydrochloride,Metindol,Osmosin
D008297 Male Males
D004148 Dioxolanes
D005744 Gastric Acid Hydrochloric acid present in GASTRIC JUICE. Hydrochloric Acid, Gastric,Acids, Gastric,Acids, Gastric Hydrochloric,Gastric Acids,Gastric Hydrochloric Acid,Gastric Hydrochloric Acids,Hydrochloric Acids, Gastric
D005769 Gastrointestinal Motility The motor activity of the GASTROINTESTINAL TRACT. Intestinal Motility,Gastrointestinal Motilities,Intestinal Motilities,Motilities, Gastrointestinal,Motilities, Intestinal,Motility, Gastrointestinal,Motility, Intestinal
D006168 Guinea Pigs A common name used for the genus Cavia. The most common species is Cavia porcellus which is the domesticated guinea pig used for pets and biomedical research. Cavia,Cavia porcellus,Guinea Pig,Pig, Guinea,Pigs, Guinea
D006635 Histamine H2 Antagonists Drugs that selectively bind to but do not activate histamine H2 receptors, thereby blocking the actions of histamine. Their clinically most important action is the inhibition of acid secretion in the treatment of gastrointestinal ulcers. Smooth muscle may also be affected. Some drugs in this class have strong effects in the central nervous system, but these actions are not well understood. Antihistaminics, H2,H2 Receptor Blockader,Histamine H2 Antagonist,Histamine H2 Blocker,Histamine H2 Receptor Antagonist,Histamine H2 Receptor Antagonists,Histamine H2 Receptor Blockader,Histamine H2 Receptor Blockaders,Antagonists, Histamine H2,Blockaders, Histamine H2 Receptor,H2 Receptor Blockaders,Histamine H2 Blockers,Receptor Antagonists, Histamine H2,Receptor Blockaders, H2,Antagonist, Histamine H2,Blockader, H2 Receptor,Blockaders, H2 Receptor,Blocker, Histamine H2,Blockers, Histamine H2,H2 Antagonist, Histamine,H2 Antagonists, Histamine,H2 Antihistaminics,H2 Blocker, Histamine,H2 Blockers, Histamine,Receptor Blockader, H2
D006851 Hydrochloric Acid A strong corrosive acid that is commonly used as a laboratory reagent. It is formed by dissolving hydrogen chloride in water. GASTRIC ACID is the hydrochloric acid component of GASTRIC JUICE. Hydrogen Chloride,Muriatic Acid,Acid, Hydrochloric,Acid, Muriatic,Chloride, Hydrogen
D000431 Ethanol A clear, colorless liquid rapidly absorbed from the gastrointestinal tract and distributed throughout the body. It has bactericidal activity and is used often as a topical disinfectant. It is widely used as a solvent and preservative in pharmaceutical preparations as well as serving as the primary ingredient in ALCOHOLIC BEVERAGES. Alcohol, Ethyl,Absolute Alcohol,Grain Alcohol,Alcohol, Absolute,Alcohol, Grain,Ethyl Alcohol
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

R Shinkawa, and T Kiso, and H Kataoka, and T Isoi, and T Kakita, and T Shogaki, and Y Ohtsubo
May 1990, Nihon yakurigaku zasshi. Folia pharmacologica Japonica,
R Shinkawa, and T Kiso, and H Kataoka, and T Isoi, and T Kakita, and T Shogaki, and Y Ohtsubo
May 1975, Gut,
R Shinkawa, and T Kiso, and H Kataoka, and T Isoi, and T Kakita, and T Shogaki, and Y Ohtsubo
December 1979, Gastroenterologia Japonica,
R Shinkawa, and T Kiso, and H Kataoka, and T Isoi, and T Kakita, and T Shogaki, and Y Ohtsubo
January 1992, Nihon rinsho. Japanese journal of clinical medicine,
R Shinkawa, and T Kiso, and H Kataoka, and T Isoi, and T Kakita, and T Shogaki, and Y Ohtsubo
January 1985, Arzneimittel-Forschung,
R Shinkawa, and T Kiso, and H Kataoka, and T Isoi, and T Kakita, and T Shogaki, and Y Ohtsubo
January 1984, European journal of clinical pharmacology,
R Shinkawa, and T Kiso, and H Kataoka, and T Isoi, and T Kakita, and T Shogaki, and Y Ohtsubo
January 1986, European journal of clinical pharmacology,
R Shinkawa, and T Kiso, and H Kataoka, and T Isoi, and T Kakita, and T Shogaki, and Y Ohtsubo
February 1987, Biochimica et biophysica acta,
R Shinkawa, and T Kiso, and H Kataoka, and T Isoi, and T Kakita, and T Shogaki, and Y Ohtsubo
May 1976, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
R Shinkawa, and T Kiso, and H Kataoka, and T Isoi, and T Kakita, and T Shogaki, and Y Ohtsubo
January 1983, Polish journal of pharmacology and pharmacy,
Copied contents to your clipboard!